Silva Pharmaceuticals Past Earnings Performance
Past criteria checks 0/6
Silva Pharmaceuticals's earnings have been declining at an average annual rate of -31%, while the Pharmaceuticals industry saw earnings growing at 9% annually. Revenues have been declining at an average rate of 2.3% per year.
Key information
-31.0%
Earnings growth rate
-31.5%
EPS growth rate
| Pharmaceuticals Industry Growth | 11.0% |
| Revenue growth rate | -2.3% |
| Return on equity | -1.3% |
| Net Margin | -5.1% |
| Last Earnings Update | 31 Mar 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How Silva Pharmaceuticals makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Mar 24 | 612 | -31 | 200 | 0 |
| 31 Dec 23 | 638 | -28 | 197 | 0 |
| 30 Sep 23 | 671 | 0 | 192 | 0 |
| 30 Jun 23 | 717 | 33 | 186 | 0 |
| 31 Mar 23 | 745 | 57 | 177 | 0 |
| 31 Dec 22 | 749 | 78 | 176 | 0 |
| 30 Sep 22 | 760 | 89 | 174 | 0 |
| 30 Jun 22 | 779 | 102 | 175 | 0 |
| 31 Mar 22 | 805 | 119 | 181 | 0 |
| 31 Dec 21 | 793 | 115 | 179 | 0 |
| 30 Sep 21 | 788 | 112 | 177 | 0 |
| 30 Jun 21 | 799 | 120 | 172 | 0 |
| 31 Mar 21 | 780 | 116 | 153 | 0 |
| 31 Dec 20 | 776 | 118 | 153 | 0 |
| 30 Sep 20 | 788 | 126 | 150 | 0 |
| 30 Jun 20 | 763 | 119 | 158 | 0 |
| 31 Mar 20 | 769 | 126 | 164 | 0 |
| 31 Dec 19 | 767 | 133 | 153 | 0 |
| 30 Sep 19 | 756 | 131 | 150 | 0 |
| 30 Jun 19 | 732 | 143 | 144 | 0 |
| 31 Mar 19 | 725 | 136 | 136 | 0 |
| 31 Dec 18 | 707 | 125 | 132 | 0 |
| 30 Sep 18 | 695 | 123 | 129 | 0 |
| 30 Jun 18 | 685 | 93 | 128 | 0 |
| 31 Mar 18 | 687 | 100 | 126 | 0 |
| 30 Jun 17 | 602 | 80 | 114 | 0 |
| 30 Jun 16 | 586 | 70 | 88 | 0 |
Quality Earnings: SILVAPHL is currently unprofitable.
Growing Profit Margin: SILVAPHL is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: SILVAPHL is unprofitable, and losses have increased over the past 5 years at a rate of 31% per year.
Accelerating Growth: Unable to compare SILVAPHL's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: SILVAPHL is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (-2.2%).
Return on Equity
High ROE: SILVAPHL has a negative Return on Equity (-1.34%), as it is currently unprofitable.